The binding of radiolabeled glucagon to rat brain membranes was investigated. Regional distribution studies indicate higher specific binding of l5I-labeled monoiodoglucagon to olfactory tubercule, hippocampus, anterior pituitary, and amygdala membranes, with somewhat lower binding to membranes from septum, medulla, thalamus, olfactory bulb, and hypothalamus. 1251-labeled glucagon bound to rat brain synaptic plasma membrane fractions with high affinity (KD = 2.24 nM). Specific binding was greater to synaptosomal membrane fractions relative to myelin, mitochondrial nuclear, or microsomal fractions. Inclusion of 0.1 mM GTP in the binding assay reduced the glucagon binding affinity (KD = 44.5 nM). Several neuropeptides and other neuroactive substances tested did not affect binding of labeled glucagon to brain membranes. Three different glucagon analogs inhibited labeled glucagon binding. Synthetic human pancreatic growth hormone-releasing factor, hpGRF-44, also inhibited binding, although the concentration required for half-maximal displacement was 100-fold higher than for native glucagon. Addition of glucagon to brain membranes resulted in -3-fold maximal activation of adenylate cyclase over basal levels. Glucagon at a concentration of 4.74 nM was required for half-maximal activation of pituitary membrane adenylate cyclase. These findings provide evidence for rat brain binding sites that respond to the pancreatic form of glucagon and can transduce this binding into the activation of adenylate cyclase.
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Glucagon, a 29-amino acid peptide product of the "A" cells of the endocrine pancreas, regulates plasma fuel concentrations, acting as a counter-regulatory hormone to insulin (1) . The most widely studied target cell for glucagon is the hepatocyte to whose plasma membrane receptors it binds to bring about activation of adenylate cyclase (2) . Glucagon is a member of a family of evolutionarily related hormones (3) . Higher molecular weight forms of glucagon isolated from the gastrointestinal tract (1, 4, 5) and pancreatic glucagon may be derived from a common precursor by tissue-specific processing (6) .
Peptide hormones earlier thought to be secretions specific to the gastro-entero-pancreatic system are increasingly being found in the mammalian brain (7, 8) . There have been several reports of glucagon and/or glucagon-like immunoreactivities in the central nervous system of rats (9) (10) (11) (12) and other mammals, including humans (13) (14) (15) (16) (17) , and in the retina of goldfish, frog, and pigeon (18) . We are unaware of any study identifying glucagon receptors in nervous tissue. We have, therefore, sought to determine the existence of such receptors as well as their regional and subcellular distribution and to partially characterize them in the rat brain.
MATERIALS AND METHODS
Porcine glucagon was a gift from Eli Lilly. Synthetic human pancreatic growth hormone-releasing factor, hpGRF-44, was graciously provided by A. Felix (Hoffmann-La Roche). Glucagon analogs, Ne-acetimidoglucagon (19) and des-Hisl-Neacetimidoglucagon were prepared as described by Flanders et al. (19) ; [S-methyl-Met27]glucagon was prepared as described by England et al. (20) . 1,3,4,6-Tetrachloro-3,6-diphenylglycouril (IODO-GEN) was purchased from Pierce, and cellulose acetate oxoid membrane filters were from Oxoid (Columbia, MD). Ultrapure-grade sucrose came from Schwarz/Mann. Theophylline and dithiothreitol were from Sigma, and ATP and GTP were from Calbiochem. Creatine phosphate and creatine phosphokinase came from Boehringer Mannheim.
Preparation of 125I-Labeled Monoiodoglucagon (1251-Monoiodoglucagon). Purified porcine glucagon was iodinated by using IODO-GEN and 1251-monoiodoglucagon was purified as described by England et al. (20) to provide a homogeneous and stable derivative with a specific activity of "=8 x 105 cpm/pmol.
Preparation of Brain Membranes. Male Sprague-Dawley rats weighing 300-350 g were decapitated, and their brains were rapidly removed and placed on ice. Separate identified regions were macroscopically dissected. Routinely, individual or pooled regions (as described in figure legends) were homogenized in 10 vol of a solution containing 1 mM dithiothreitol, 0.1% bovine serum albumin, 30 mM Tris HCl (pH 7.5) (buffer A) at 40C in a Teflon glass homogenizer. For subcellular distribution studies, pooled regions were homogenized in 10 vol of 0.32 M sucrose and fractions were prepared according to the method of Gray and Whittaker (21) . All fractions were kept on ice and assayed immediately. Membrane protein concentration was determined by the method of Markwell et al. (22) .
Preparation of Liver Plasma Membranes. Partially purified liver plasma membranes were prepared according to the method of Neville (23) through step 11 as described by Pohl (24) . The final pellet was resuspended in 1 mM NaHCO3 and divided into aliquots (-6 mg of protein) that were stored in liquid nitrogen and used within 2 months.
Glucagon Binding Assay. The binding assay was essentially that of England et al. (20) . The incubation buffer contained 1 mg of bovine serum albumin per ml, 1 mM dithiothreitol, 30 mM Tris-HCl (pH 7.5). The incubation mixture, of total volume 1 ml, contained 200 ,g of brain membranes or thawed liver plasma membranes, as indicated, and 0.13 pmol (_1 x 105 cpm) of 1251-monoiodoglucagon. Other additions are given in figure legends. Reaction mixtures were incubated at 4'C for 30 min and then rapidly (<5 s) vacuum filtered through Oxoid membrane filters (0.45 ,um) previously soaked for at least 30 min in bovine serum albumin at 100 mg/ml. Each filter was washed twice with 3 ml of ice-cold incubation buffer, dried, and assayed for radioactivity in a Beckmann Biogamma Counter.
Nonspecific binding measured in the presence of 1 AM unAbbreviations: IC50, concentration required for half-maximal inhibition of binding; hpGRF, human pancreatic growth hormone-releasing factor. *To whom reprint requests should be addressed.
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labeled peptide was 25-30% of total and was subtracted from the total to give specific binding. Results are analyzed by curve fitting the data to a four-parameter equation describing a sigmoidal dose-response curve (25) . Competition assays were performed at least twice. The standard deviation of each assay point performed in duplicate was <5%.
Adenylate Cyclase Assay. The adenylate cyclase assay medium contained the following in a final volume of 0.1 ml: 2 mM ATP, 10 mM MgCl2, 1 mM dithiothreitol, 10 mM GTP, 1 mM theophylline, 2 mM EDTA, 30 mM Tris-HCl (pH 7.5), and an ATP regenerating system consisting of 5 mM creatine phosphate and creatine phosphokinase at 0.3 mg/ml (9.3 units/ml). Peptides diluted in 0.1% bovine serum albumin/ Binding to Subcellular Fractions. Regions that displayed high specific binding were pooled and subjected to subcellular fractionation procedures (21, 27 ) that yield fractions enriched in morphologically identifiable components ( Table 2 ). As shown in Table 2 , specific binding of labeled glucagon to the various fractions differed significantly. In three experiments the specific binding of 125I-monoiodoglucagon was higher in the P2 fraction than in the P1 or P3 fraction and was higher in the P2B fraction than in the P2A or P2C fraction.
To characterize the binding affinity, subcellular fractions were used in competition assays. As illustrated in Fig. 1 , the half-maximal concentrations required for the binding of glu- Inclusion of 0.1 mM GTP shifted the concentration of unlabeled glucagon required for the half-maximal displacement of '251-monoiodoglucagon from 1.01 nM to 28.7 nM for liver plasma membranes and from 5.01 nM to 44.5 nM for brain membranes (Fig. 2) compete with 125I-monoiodoglucagon binding to both brain and liver plasma membrane preparations (data not shown).
However, a 100 times higher concentration of hpGRF-44 was required for half-maximal displacement (IC50 = 447 nM with brain homogenate and IC50 = 158 nM with liver plasma membranes). Three glucagon analogs tested each inhibited 1251-monoiodoglucagon binding but required concentrations higher than native glucagon to bring about half-maximal displacement (Fig. 3) . N8-acetimidoglucagon, a glucagon derivative having an acetimidyl group at the e-amino group of lysine 12 (19) was 1/10th as effective as native glucagon in competing for 1251-monoiodoglucagon binding (IC50 = 31.6 nM). With des-Hisl-Ne-acetimidoglucagon, prepared by manual Edman degradation of Ne-acetimidoglucagon (19) , and [S-methyl-Met27]glucagon (20) half-maximal displacement occurred at 398 nM and 296 nM, respectively. Adenylate Cyclase Activation. Dose-response curves for the activation of adenylate cyclase by glucagon in different tissues are shown in Fig. 4 . The concentration of glucagon required for half-maximal activation was 3.65 nM with partially purified liver plasma membranes as compared with 5.63 nM with rat olfactory and pituitary homogenates. 
DISCUSSION
Although the presence of glucagon and glucagon-like peptides in brain has been reported (9) (10) (11) (12) (13) (14) (15) (16) (17) , to our knowledge glucagon receptor identification and localization in the central nervous system has not been reported previously.
Elements within the rat brain limbic system (olfactory tubercule and bulb, hippocampus, amygdala, and septum), as well as hypothalamus, thalamus, medulla, and anterior pituitary membranes displayed significant glucagon binding (Table 1). A neuronal role for glucagon is suggested by these data and the higher binding of glucagon to subcellular fractions enriched in synaptic plasma membranes (Table 2) . Differential specific binding of radiolabeled insulin to blood vessels in different brain regions has been reported (29) . However, in our study it is an unlikely possibility that some contamination of the synaptosomal-enriched (P2B) fraction by blood vessels or cells could account for the high glucagon binding to this fraction inasmuch as the P1 fraction (containing cellular debris) displayed little binding (Table 2) . Ultrastructural demonstration of the binding of glucagon to recognizable synaptic elements is desirable. Glucagon bound to liver and synaptic plasma membranes with similar affinity (KD 2 nM) and binding affinity for both membranes was diminished in the presence of 0.1 mM GTP ( Figs. 1 and 2) .
Insulin, somatostatin, vasopressin, vasoactive intestinal polypeptide, and several neurotransmitters examined did not inhibit binding pf glucagon to rat brain homogenates. The regional distributions in mammalian brains of glucagon-related peptides such as vasoactive intestinal polypeptide (30) , secretin (31) , gastrin (32) , and PHI-27 (33) differ from that for glucagon (9) (10) (11) (12) (13) (14) (15) (16) (17) . hpGRF-44, which is also a member of the glucagon-secretin family of evolutionarily related peptides, did inhibit glucagon binding. However, 100 times higher concentration of hpGRF-44 compared to glucagon was required to bring about half-maximal displacement of 1251_ monoiodoglucagon from brain and liver membranes, ruling out the possibility of hpGRF exerting its physiological effects through these receptors, which exhibit a high affinity for glucagon. Synthetic hpGRF-44 is also known to bind with low affinity to vasoactive intestinal polypeptide receptors in rat and human intestinal epithelial membranes (34) .
In competition assays the amino-terminal, carboxyl-terminal, and centrally modified glucagon derivatives displayed lower affinities for brain homogenates compared to native glucagon. This is consistent with the observation that virtually the whole glucagon molecule participates in the hepatic receptor regulation process (20) . The rank order of potency of glucagon analogs examined for brain membranes (native glucagon > Ne-acetimidoglucagon > [S-methyl-Met27]glucagon > des-Hisl-Ne-acetimidoglucagon) (Fig. 3 (10, (12) (13) (14) (15) (16) (17) , thalamus (10-15), septum (10), and medulla (11, 15, 16) , which in our study also have glucagon receptors. To date, local synthesis or uptake of glucagon in brain has not been demonstrated. Tager et al. (11) have suggested that glucagon-containing peptides found in rat brain have undergone intestinal rather than pancreatic type of processing (6). Dom et al. (12) were unable to distinguish between pancreatic and gut-type glucagon, and Tominaga et al. (9) and Conlon et al. (13) found pancreatic glucagon in addition to gut-type glucagon in mammalian brains. However, the central nervous system binding sites that we have identified in this study fulfill the criteria of defined localization, high affinity, high specificity, and biological response to the pancreatic form of glucagon.
Several recent studies have demonstrated pancreatic glucagon-induced release of somatostatin from perifused hypothalamus (35, 36) and cAMP formation in neuroblastoma x glioma hybrid cells (37) . Other studies have shown somatostatin release from the median eminence into the hypophyseal portal vessel by pancreatic glucagon (38) . Somatostatin release has also been shown to be cAMP dependent (39, 40) . The above cited reports and our finding of glucagon-mediated cAMP formation suggest that glucagon in the hypothalamus may be involved in the release of somatostatin through cAMP-dependent mechanisms.
